Fără conexiune la internet — se afișează versiunea salvată a paginii.

Scilex Holding Co…

USUSD
← Către Filtru

Scilex Holding Company (US:SCLX) — Biotechnology: Biological Products (No Diagnostic Substances). Numărul de burse pe care se tranzacționează acțiunile companiei: 1. Pe această pagină — preț și grafic, dividende, principalii deținători și istoricul numărului de acțiuni.

Despre Companie

Site Web
scilexholding.com
Relații cu Investitorii
scilexholding.com/investors/contact-investor-relations
Sector
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Sediu Central
PALO ALTO, United States
Director General
Henry H. Ji
Angajați
34
Acțiuni în Circulație
8.49 mil. la 2026-08-10
Free Float
5.69 mil.
Capitalizare de Piață
31.02 mil. USD
Insideri
11.67%
Investitori Instituționali
8.52%
Industrie (SIC)
Biological Products, (No Diagnostic Substances)
P/E
pierdere
Rata de Distribuire
pierdere
FCF
−17.8 mil. USD
Plăți / FCF
FCF < 0
Datorie
28.8 mil. USD
Vechimea Dividendelor
—
Câștiguri, FCF și dividende plătite — pentru cele 12 luni până la 30.06.2026 (cel mai recent raport al companiei).
NAV
−43.83 USD
Balance sheet date30.06.2026
Assets254 mil. USD
− Liabilities564 mil. USD
= Total equity−310 mil. USD
− Non-controlling interests−2.17 mil. USD
= NAV (equity of the company's shareholders)−308 mil. USD
− Goodwill13.5 mil. USD
− Intangible assets57.6 mil. USD
= Tangible NAV−379 mil. USD
Acțiuni7 034 737
NAV per share−43.83 USD
Tangible NAV per share−53.93 USD
Equity is negative: liabilities exceed assets (often because of large share buybacks). P/NAV is not calculated.
NAV history
Balance sheet dateNAVNAV per share
30.06.2026−308 mil. USD−43.83 USD
31.03.2026−249 mil. USD−29.35 USD
31.12.2025−208 mil. USD−29.54 USD
30.09.2025−177 mil. USD−29.75 USD
30.06.2025−249 mil. USD−45.29 USD
31.03.2025−211 mil. USD−38.50 USD
31.12.2024−193 mil. USD−36.80 USD
30.09.2024−211 mil. USD−1.60 USD
Descriere

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.

publicitate

Burse și Simboluri

BursăSimbolMonedăPrețTip
US USA StocksSCLXUSD2.88 +2.86%acțiuni ordinare

Preț pe 3 Luni

US:SCLX · USD
zi de creștere zi de scădere data ex-dividend data plățiiTreceți cu mouse-ul / atingeți o zi — prețurile de deschidere, închidere, maxim și minim

Dividende

Nu s-au găsit plăți de dividende (verificat 15.10.2026). Probabil că societatea nu plătește dividende.

Cei Mai Mari Acționari

DeținătorParticipațieAcțiuniData Raportului
JI HENRY H (Officer and…≈8.02%680 8842024-10-31
Vanguard Capital Managem…3.55%301 2922026-06-30
SHAH JAISIM (Chief Execu…≈3.48%295 2152024-12-18
VANGUARD INDEX FUNDS-Van…2.56%217 5102026-06-30
CHUN JAY (Director)≈1.33%112 5112024-10-18
Blackrock Inc.1.29%109 4172026-06-30
VANGUARD INDEX FUNDS-Van…0.9%76 2302026-06-30
Vanguard Fiduciary Trust…0.54%45 8222026-06-30
Jacobs Levy Equity Manag…0.48%41 1632026-06-30
State Street Corporation0.42%35 3762026-06-30
UBS Group AG0.39%33 3762026-06-30
Renaissance Technologies…0.39%33 0642026-06-30
Citadel Advisors Llc0.32%27 4972026-06-30
WU YUE ALEXANDER (Direct…≈0.29%25 0002024-10-17
iShares Trust-iShares Mi…0.28%23 9352026-08-31
MA STEPHEN HOI (Chief Fi…≈0.27%22 8402024-10-16
Price (T.Rowe) Associate…0.25%20 9202026-06-30
Ashton Thomas Private We…0.22%18 4822026-06-30
-Price (T.Rowe) U.S. Equ…0.17%14 0202026-06-30
T. ROWE PRICE INDEX TRT,…0.08%6 9002026-06-30
VANGUARD Inst. INDEX Fd.…0.04%3 8052026-06-30
VANGUARD VALLEY FORGE FU…0.04%3 7472026-06-30
FOLLOWWILL DORMAN (Direc…≈0.03%2 3002024-10-18
LEMUS DAVID (Director)≈0.02%2 0002024-10-17
EQ Advisors Trust-1290 V…0.02%1 6832026-06-30
Brighthouse Funds Trust…0.01%6272026-06-30
STATE STREET Inst. INVES…0%1202026-06-30
SCILEX HOLDING CO (Benef…—244.45 mil.2025-12-30